SAB expects to have initial lots of their SAB-185 therapeutic candidate available for clinical evaluation as early as summer 2020 and has activated its network of collaborators to prepare for rapid ...
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results